HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Tetsuro Shishido Selected Research

Diacylglycerol Kinase

1/2014Diacylglycerol kinase α exacerbates cardiac injury after ischemia/reperfusion.
2/2007Cardiac-specific overexpression of diacylglycerol kinase zeta attenuates left ventricular remodeling and improves survival after myocardial infarction.
1/2006Cardiac-specific overexpression of diacylglycerol kinase zeta prevents Gq protein-coupled receptor agonist-induced cardiac hypertrophy in transgenic mice.
3/2005Adenovirus-mediated overexpression of diacylglycerol kinase-zeta inhibits endothelin-1-induced cardiomyocyte hypertrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Tetsuro Shishido Research Topics

Disease

16Heart Failure
11/2014 - 11/2004
8Myocardial Infarction
01/2015 - 12/2003
6Cardiomegaly (Heart Hypertrophy)
01/2014 - 10/2005
5Inflammation
05/2014 - 07/2006
3Reperfusion Injury
12/2015 - 05/2006
3Coronary Artery Disease (Coronary Atherosclerosis)
09/2014 - 01/2014
3Body Weight (Weight, Body)
02/2014 - 01/2006
3Ischemia
01/2014 - 04/2006
3Fibrosis (Cirrhosis)
09/2013 - 12/2003
2Peripheral Arterial Disease
12/2015 - 10/2015
2Atrial Fibrillation
10/2015 - 08/2012
2Cardiomyopathies (Cardiomyopathy)
05/2015 - 08/2008
2Cardiovascular Diseases (Cardiovascular Disease)
01/2015 - 01/2011
2Insulin Resistance
01/2014 - 10/2006
2Hypertrophy
09/2013 - 03/2005
2Ventricular Remodeling
02/2007 - 12/2003
2Renal Insufficiency (Renal Failure)
10/2005 - 10/2005
1Shock
05/2015
1No-Reflow Phenomenon
01/2015
1Obesity
05/2014
1Anemia
05/2014
1Genomic Instability
09/2013
1Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/2013
1Stroke (Strokes)
08/2012
1Death (Near-Death Experience)
07/2012
1Heart Injuries
07/2012
1Cardiac Sudden Death (Sudden Cardiac Arrest)
01/2011
1Kidney Diseases (Kidney Disease)
01/2011
1Spasm (Spasms)
01/2011
1Neoplasms (Cancer)
11/2010
1Diabetes Mellitus
08/2008
1Ventricular Dysfunction
06/2008
1Vascular System Injuries
07/2006
1Hyperglycemia
04/2006

Drug/Important Bio-Agent (IBA)

4Carrier Proteins (Binding Protein)IBA
12/2015 - 07/2005
4Diacylglycerol KinaseIBA
01/2014 - 03/2005
4Angiotensin IIIBA
09/2013 - 10/2005
3Cystatin CIBA
10/2015 - 10/2005
3Brain Natriuretic Peptide (Natrecor)FDA Link
05/2014 - 08/2005
3Protein Kinase CIBA
01/2014 - 03/2005
3DNA (Deoxyribonucleic Acid)IBA
09/2013 - 10/2005
2Troponin T (T, Troponin)IBA
12/2015 - 07/2012
2PTX3 proteinIBA
12/2015 - 01/2013
2CreatinineIBA
10/2015 - 10/2005
2HMGB1 Protein (HMG1)IBA
05/2015 - 09/2013
2Pregnancy-Associated Plasma Protein-A (PAPP-A)IBA
01/2015 - 10/2011
2AdipokinesIBA
05/2014 - 01/2014
2midkineIBA
01/2014 - 04/2010
2UbiquitinIBA
02/2012 - 06/2008
2Reactive Oxygen Species (Oxygen Radicals)IBA
07/2011 - 07/2006
290-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 90 kDa)IBA
08/2008 - 05/2006
2Phenylephrine (Neo-Synephrine)FDA LinkGeneric
02/2007 - 01/2006
2Collagen Type I (Type I Collagen)IBA
02/2007 - 12/2003
2Messenger RNA (mRNA)IBA
04/2006 - 12/2003
2Atrial Natriuretic Factor (ANF)IBA
01/2006 - 03/2005
2Heat-Shock Proteins (Heat-Shock Protein)IBA
11/2004 - 12/2003
1landiololIBA
10/2015
1DNA-Binding Proteins (DNA Binding Protein)IBA
05/2015
1Caspase 3 (Caspase-3)IBA
05/2015
1HSP27 Heat-Shock ProteinsIBA
05/2015
1Doxorubicin (Adriamycin)FDA LinkGeneric
05/2015
1ThioredoxinsIBA
11/2014
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
09/2014
13-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)IBA
09/2014
1IronIBA
05/2014
1AdiponectinIBA
05/2014
1Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
03/2014
1Plasminogen Activator Inhibitor 1IBA
03/2014
1salicylhydroxamic acid (SHAM)IBA
02/2014
1triphenyltetrazoliumIBA
01/2014
1Evans Blue (Blue, Evans)FDA Link
01/2014
1DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA
01/2014
1CytokinesIBA
01/2013
1omega-Chloroacetophenone (Mace)IBA
01/2013
1Biological Markers (Surrogate Marker)IBA
08/2012
1valsartan (Vals)FDA Link
01/2011
1NeopterinIBA
11/2010
1human CHI3L1 proteinIBA
11/2010
1Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
08/2008
1ThrombinFDA Link
11/2007
1Thromboplastin (Tissue Factor)IBA
11/2007
1pentosidineIBA
04/2007
1Collagen Type III (Type III Collagen)IBA
02/2007
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
10/2006
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
10/2006
1Heme Oxygenase-1IBA
10/2006
1Type 1 Angiotensin ReceptorIBA
04/2006
1Captopril (Capoten)FDA LinkGeneric
04/2006
1olmesartanIBA
04/2006
1Streptozocin (Streptozotocin)FDA Link
04/2006
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
04/2006
1Gq-G11 GTP-Binding Protein alpha Subunits (Gq Protein)IBA
01/2006
1Phosphotransferases (Kinase)IBA
10/2005
1pitavastatin (itavastatin)FDA Link
10/2005

Therapy/Procedure

2Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
07/2012 - 01/2011
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
01/2015
1Angioplasty (Angioplasty, Transluminal)
07/2006
1Nephrectomy
10/2005
1Ligation
12/2003